NCT01834911

Effect of Tetrabenazine on Stroop Interference in HD

Effect of Tetrabenazine on Stroop Interference in Huntington Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: New York Medical College · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.

Conditions

• Huntington Disease

Interventions

Type	Name	Description
DRUG	Tetrabenazine withdrawal	Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.

Timeline

• Start date: 2013-03-01
• Primary completion: 2018-01-01
• Completion: 2018-01-01
• First posted: 2013-04-18
• Last updated: 2025-05-28
• Results posted: 2025-05-28

Locations

1 site across 1 country: United States